Zura Bio Limited (ZURA)
Zura Bio Limited operates in the Biotechnology industry of the Healthcare sector, headquartered in Henderson, NV, US. The stock last traded at $5.82, up 4.59% on the session, giving a market capitalisation of $552.4M. On trailing twelve-month figures it carries a trailing P/E of -5.15, a net margin of 0.0%. Its beta of -0.04 implies it has historically moved less than the broad market.
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
Zura Bio Limited is most often compared with the following Healthcare names: